BioSpace News Archive

Penumbra, Inc. announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below.

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of new data from its small molecule programs enhancing the HGF/MET neurotrophic system.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023.

Gracell Biotechnologies Inc. announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2022 with the U.S. Securities and Exchange Commission on April 25, 2023.

10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10, at 2:20 p.m. Pacific Time.

Haemonetics Corporation announced that the Company intends to publish fourth quarter and fiscal year 2023 financial results at 6:00 am ET on Thursday, May 11, 2023.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 17,600 shares of the Company’s common stock at an exercise price per share of $19.31, which was the closing price on April 24, 2023, and restricted stock units to acquire a total of 8,800 shares of the Company’s common stock.

The Board of Directors of PerkinElmer, Inc. declared a regular quarterly dividend of $0.07 per share of common stock.

Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET.